BioCentury This Week

BioCentury Podcasts
  • 4.0 (1)
  • BIOWISSENSCHAFTEN
  • WÖCHENTLICH
BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

  1. Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update

    VOR 1 TAG

    Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update

    Positive vibes about biotech emanating from the Jefferies Healthcare Conference were overshadowed by the uncertainty that is ahead because of the result of the U.S. elections. On the latest BioCentury This Week, BioCentury’s editors discuss how the unconventional cabinet nominations of the incoming Trump administration have cast a pall over what had been growing enthusiasm for the prospects of the biotech sector. Washington Editor Steve Usdin also discusses what the nomination of Marty Makary...

    27 Min.
  2. Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

    19. NOV.

    Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals

    Giving RFK Jr. control of HHS would be disastrous, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Expanding on his Editor’s Commentary, Usdin explains why Kennedy would be an unmitigated disaster for FDA, NIH and CMS, for biopharmas and for patients. He calls on biopharma leaders to speak out and affirm basic truths, even if it puts them in harm’s way.BioCentury’s editors also discuss why new data for GSK's Blenrep — an oncology therapy withdrawn two years ag...

    30 Min.
  3. Ep. 264 - Prepping for Trump & Alzheimer's Ethics

    12. NOV.

    Ep. 264 - Prepping for Trump & Alzheimer's Ethics

    Trump 2.0 presents opportunities and challenges for leaders of the biopharma industry, which needs effective public policy to thrive. On the latest BioCentury This Week, BioCentury Washington Editor Steve Usdin explains what those opportunities are and lays out the potential impact on the public policy environment, which could have repercussions on FDA and beyond.BioCentury’s editors then analyze how companies, academics and advocates are pushing back on claims that they should have disclosed...

    29 Min.
  4. Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

    5. NOV.

    Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser

    It’s too soon to conclude anti-amyloid therapies are safe for use by Alzheimer’s patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year’s Clinical Trials on Alzheimer’s Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look lik...

    35 Min.
  5. Ep. 262 - EGFR Case Study, FDA & Politics

    29. OKT.

    Ep. 262 - EGFR Case Study, FDA & Politics

    Twenty years of innovation in therapies targeting EGFR provides a case study in how generation of differentiated products against the target can drive market growth. On the latest BioCentury This Week podcast, BioCentury’s editors discuss EGFR as a prime example of the value in best-in-class development strategies, with meaningful improvements across multiple modalities delivering substantial therapeutic benefits to patients. Analogous best-in-class opportunities aren’t limited to cancer, but...

    24 Min.
  6. Ep. 261 - China Summit: Reinventing Your China Strategy

    24. OKT.

    Ep. 261 - China Summit: Reinventing Your China Strategy

    Cross-border geopolitical tensions and a prolonged capital crunch are compelling biopharma companies from Beijing to Boston to rethink their strategies on everything from deal-making and raising capital to manufacturing and use of CROs. On a special edition of the BioCentury This Week podcast, McKinsey’s Franck Le Deu and Wendy Pan of BayHelix and Goodwin join BioCentury on the eve of next week’s eleventh annual BioCentury-BayHelix China Healthcare Summit in Shanghai to discuss the dynamics a...

    32 Min.
  7. Ep. 260 - VC Funds, New Chapter for MS, Wave's Data

    22. OKT.

    Ep. 260 - VC Funds, New Chapter for MS, Wave's Data

    At least 25 venture firms have raised a total of more than $17 billion in funds this year, with Forbion unveiling the largest-ever European biopharma fund at €1.2 billion last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how Forbion deployed its prior fund and quickly raised fresh funds and what that — and other funds — say about the state of financing private biotechs in Europe and elsewhere.The editors then assess takeaways from BioCentury’s conversation wi...

    31 Min.
  8. Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA

    15. OKT.

    Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA

    There is a growing mandate among researchers and VCs to provide proof of causal human biology for new targets. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the different strategies being deployed to identify causal links to disease using observational patient data or human cell models, including the challenges that come with each approach and the various computational methodologies companies are using.They also discuss the outcome of FDA’s advisory committee meetin...

    34 Min.
Alle anzeigen (275)

Info

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Informationen

Mehr von BioCentury Podcasts

Das gefällt dir vielleicht auch

Melde dich an, um anstößige Folgen anzuhören.

Bleib auf dem Laufenden mit dieser Sendung

Melde dich an oder registriere dich, um Sendungen zu folgen, Folgen zu sichern und die neusten Updates zu erhalten.
Wähle ein Land oder eine Region aus

Afrika, Naher Osten und Indien

Asien/Pazifik

Europa

Lateinamerika und Karibik

USA und Kanada